All In Biotech

Drug Trial Radar · NCT07725575

Efficacy of Intrathecal Administration of Budesonide to Prevent Bronchopulmonary Dysplasia

Efficacy Of Intratracheal Administration Of Budesonide To Prevent Bronchopulmonary Dysplasia In Neonate With Gestational Age Less Than 32 Weeks/Birth Weight Less Than 1500 Grams With Respiratory Distress Syndrome Who Received Surfactant

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Nov 1, 2024

Primary completion

Apr 24, 2025

Study completion Jun 1, 2025

Sponsor

Lead sponsor
Universitas IndonesiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, up to 48 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if budesonide works to prevent bronchopulmonary dysplasia in newborn less than 32 weeks gestational age or birth weight less than 1500 g with respiratory distress syndrome who needs surfactants. Does budesonide lower the incidence of bronchopulmonary dysplasia? What medical problems do participants have after given budesonide? Researchers will compare intratracheal budesonide and surfactant to intratracheal surfactant only to see if budesonide works to prevent bronchopumonary dysplasia. Participants will: Given intratracheal budesonide and surfactant and followed up until 36 weeks of post menstrual age to determine whether they have bronchopulmonary dysplasia or not

Conditions

  • Bronchopulmonary Dysplasia (BPD)

Interventions

  • ExperimentalDrug

    budesonide 25 mg/kg + beractant 100 mg/kg administered intratracheal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bronchopulmonary dysplasiaTime frame: subject collection: 8 months, data processing 1 month, publication 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cipto Mangunkusumo Hospital

    Jakarta, DKI Jakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.